Wednesday, November 15, 2017 LY.12 citation Bosch M, Akhter A, Chen BE, Mansoor A, LeBrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA. A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma (ONLINE). Haematologica 2017. http://www.haematologica.org/content/early/2017/10/31/haematol.2017.179309.abstract A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation. SC.20 citation Chow R, Ding K, Ganesh V, Meyer RM, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, van Acht M, Wanders R, Babington S, Demas WF, Wilson CF, Wong RKS, Brundage M, Zhu L, Chow E. Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial (ONLINE). Radiotherapy and Oncology 2017. http://www.sciencedirect.com/science/article/pii/S016781401732635X A Phase III International Randomized Trial of Single Versus Multiple Fractions for Re-Irradiation of Painful Bone Metastases.
